GH Latest Press Releases

-- February 19, 2026 --

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Business Wire 4:05 PM

-- February 12, 2026 --

Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open PRNewswire 2:35 PM

-- February 10, 2026 --

AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation Globe Newswire 9:29 AM

-- February 3, 2026 --

Guardant Health to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- February 2, 2026 --

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions Business Wire 8:05 AM

-- January 29, 2026 --

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 Business Wire 4:05 PM

-- January 22, 2026 --

Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for BRAFTOVI (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer Business Wire 8:05 AM

-- January 19, 2026 --

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform Business Wire 8:05 AM

-- January 11, 2026 --

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results Business Wire 5:00 PM

-- January 8, 2026 --

Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families Business Wire 8:05 AM

-- December 29, 2025 --

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:05 PM

-- December 11, 2025 --

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S. Business Wire 8:05 AM

-- December 9, 2025 --

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy Business Wire 8:05 AM

-- December 5, 2025 --

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium Business Wire 8:05 AM

-- November 12, 2025 --

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access Business Wire 8:05 AM

-- November 10, 2025 --

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring Business Wire 8:05 AM

-- November 7, 2025 --

Guardant Health to Participate in Upcoming Investor Conferences Business Wire 8:00 AM

-- November 6, 2025 --

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 6:35 PM

New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response Business Wire 8:05 AM

-- November 5, 2025 --

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients Business Wire 4:05 PM

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock Business Wire 2:15 AM

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering Business Wire 2:15 AM

-- November 4, 2025 --

Guardant Health Announces Proposed Public Offering of Common Stock Business Wire 4:39 PM

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033 Business Wire 4:38 PM

-- October 29, 2025 --

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Business Wire 4:05 PM

-- October 27, 2025 --

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights Business Wire 8:05 AM

-- October 26, 2025 --

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 Business Wire 3:01 PM

-- October 16, 2025 --

4 Diagnostic Stocks Targeting 25%+ Annual Growth in a $20B Market (MDCX, ILMN, EXAS, GH) AB Digital Inc 4:12 PM

-- October 15, 2025 --

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 Business Wire 4:57 PM

-- October 9, 2025 --

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 Business Wire 4:05 PM

Propel Software Accelerates Adoption of Agentic AI for PLM, QMS & PIM with Early Customers Using Live Data Business Wire 9:04 AM

-- September 29, 2025 --

FDA Approves Guardant360 CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer Business Wire 8:05 AM

-- September 24, 2025 --

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield Blood-based Screening Test in the United States Business Wire 8:05 AM